NCT02827877
Cu64-DOTA-trastuzumab PET and Markers Predicting Response to Neoadjuvant Trastuzumab + Pertuzum in HER2+ Breast Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 21 versions: 18 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Start date: Jul 15, 2016 to Feb 14, 2018
- Eligibility criteria expanded, about 12 words
- Study completion pushed from Sep 25, 2026 to Aug 26, 2027
- Minor Study completion date: Oct 16, 2025 to Sep 25, 2026v20
- Minor Study completion date: Jun 1, 2025 to Oct 16, 2025v19
- Minor Study completion date: Dec 30, 2024 to Jun 1, 2025v18
- Minor Study completion date: Dec 30, 2023 to Dec 30, 2024v17
Show 12 earlier versionsHide 12 earlier versions
- Minor Study completion date: Jun 30, 2023 to Dec 30, 2023v16
- Notable Results first posted: Mar 9, 2023
- Primary endpoints: 3 to 1
- Study completion date: Dec 31, 2021 to Jun 30, 2023
- Study title shortened, about 8 words
- Minor Primary completion date: Apr 13, 2020 to Jul 2, 2020v14
Minor Trial status: Recruiting to Active, Not Recruitingv13 Show 4 more changesShow less
- Enrollment target: estimated 20 to confirmed 18
- Primary completion date changed from estimate of Feb 2021 to Apr 13, 2020
- Study completion date: Feb 2021 to Dec 31, 2021
- Site details revised
- Notable Primary and study completion dates: Feb 2020 to Feb 2021v12
- Notable Phase: Not applicable to Phase 2
- Eligibility criteria revised
- Study description expanded, about 1 word
- Notable Primary and study completion dates: Feb 2019 to Feb 2020v10
- Minor Primary and study completion dates: Dec 2018 to Feb 2019v8
- Minor Study description revisedv7
- Notable Eligibility criteria shortened, about 5 wordsv5
- Minor Primary and study completion dates: Oct 2018 to Dec 2018
- Start date: Jul 2016 to Jul 15, 2016
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
- Eligibility criteria expanded, about 4 words
- Start date: Oct 2016 to Jul 2016
- Interventions: Chemotherapy (Drug), Copper Cu 64-DOTA-Trastuzumab (Radiation), Laboratory Biomarker Analysis (Other), Pertuzumab (Biological), Positron… to Copper Cu 64-DOTA-Trastuzumab (Radiation), Laboratory Biomarker Analysis (Other), Pertuzumab (Biological), Positron Emission Tomography…
- Study description shortened, about 44 words
- Site details revised
- Study title expanded, about 1 word
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Patients receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV on day 0. Patients undergo PET scans at 18-24 and 42-48 hours, on day 1 and day 2. Within 4 days after completion of PET scans, patients receive trastuzumab IV over 30-90 minutes weekly or every 3 weeks and pertuzumab IV over 30-60 minutes. Treatment repeats every 21 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo surgery after 6 cycles of trastuzumab and pertuzumab.
Radiation: Copper Cu 64-DOTA-Trastuzumab
Other: Laboratory Biomarker Analysis
Biologicals: Pertuzumab, Trastuzumab
Procedures: Positron Emission Tomography, Therapeutic Conventional Surgery
Sites
1 site in 1 country
- City of Hope Medical CenterDuarte, California, United States